OnKure Therapeutics, Inc. — Director's Dealing 2021

Apr 8, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Reneo Pharmaceuticals, Inc. (RPHM)
CIK: 0001637715
Period of Report: 2021-04-08

Reporting Person: O'Donnell Niall (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Preferred Stock	$		Common Stock (1034600)		Indirect
Series B Preferred Stock	$		Common Stock (829113)		Indirect
Stock option (right to buy)	$1.97	2028-04-04	Common Stock (84568)		Direct
Stock option (right to buy)	$3.76	2029-06-25	Common Stock (32403)		Direct

Footnotes

F1: All outstanding shares of Preferred Stock will automatically convert into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 4.4748 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F2: The shares held by RiverVest Venture Fund IV, L.P. ("RiverVest Fund IV") are indirectly held by RiverVest Venture Partners IV, L.P., its general partner ("RiverVest Partners IV"). RiverVest Venture Partners IV, LLC is the general partner of RiverVest Partners IV. The individual managers of RiverVest Ventures Partners IV, LLC are Jay Schmelter, John P. McKearn, Ph.D. and the Reporting Person. RiverVest Partners IV, RiverVest Venture Partners IV, LLC and each of the individual managers (including the Reporting Person) share voting and dispositive power with regard to the Company's securities directly held by RiverVest Fund IV.
The Reporting Person disclaims beneficial ownership of all shares owned by RiverVest Fund IV, except to the extent of any pecuniary interest therein.